Key clinical point: Age of onset was an important predictive factor for length of survival in multiple myeloma patients.
Major finding: The overall survival was significantly longer in young patients (median, 65 months vs. 41 months; P = .001).
Study details: A retrospective analysis of clinical characteristics, response to treatment/survival of 282 patients with active newly-diagnosed multiple myeloma.
Disclosures: The authors reported that they had no conflicts of interest.
Bove V et al. Hematol Transfus Cell Ther. 2020 Aug 20. doi: 10.1016/j.htct.2020.06.014.